Dataset related to the article "Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan"

<p>This record contains raw data related to the article &quot;Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan&quot;.</p> <p>Abstract: In terms of sacubitril/valsartan (S/V)-induced changes in heart failure with reduced&nbsp;ejection fraction (HFrEF) via three-dimensional (3D) transthoracic echocardiography (TTE) and S/V&nbsp;effects based on HF aetiology, data are lacking. We prospectively enrolled 51 HFrEF patients (24&nbsp;ischaemic, 27 non-ischaemic). At baseline and at 6-month follow-up (6MFU) after S/V treatment<br> optimisation, we assessed the N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac&nbsp;remodelling by two-dimensional (2D) and 3DTTE. In non-ischaemic patients, 2D and 3DTTE&nbsp;showed an improvement in left ventricular (LV) size and biventricular function at 6MFU vs.&nbsp;baseline: 3D-LV end-diastolic volume (EDV) 103 &plusmn; 30 vs. 125 &plusmn; 32 mL/m2 (p &lt; 0.05), 3D-LV ejection<br> fraction (EF) 40 &plusmn; 9 vs. 32 &plusmn; 5% (p &lt; 0.05), right ventricular (RV) 3D-EF 48.4 &plusmn; 6.5 vs. 44.3 &plusmn; 7.5% (p &lt;&nbsp;0.05); only the 3D method detected RV size reduction: 3D-RVEDV 63 &plusmn; 27 vs. 71 &plusmn; 30 mL/m2 (p &lt;&nbsp;0.05). In ischaemic patients, only 3DTTE showed biventricular size and LV function improvement:&nbsp;3D-LVEDV 112 &plusmn; 29 vs. 121 &plusmn; 27 mL/m2 (p &lt; 0.05), 3D-LVEF 35 &plusmn; 6 vs. 32 &plusmn; 5% (p &lt; 0.05), 3D-RVEDV&nbsp;57 &plusmn; 11 vs. 63 &plusmn; 14 mL/m2 (p &lt; 0.05); RV function did not ameliorate. In both ischaemic and nonischaemic<br> patients, diastolic function and NT-proBNP significantly improved. In HFrEF patients&nbsp;treated with S/V, 3DTTE helps to ascertain subtle changes in heart chambers&rsquo; size and function,&nbsp;which have a major impact on HFrEF prognosis. S/V has significantly different effects on LV&nbsp;function in non-ischaemic vs. ischaemic patients.</p>